Skip to main content
CING
NASDAQ Life Sciences

Falcon Creek Group Finalizes $11M Investment in Cingulate, Securing 28.5% Stake and Board Seats

Analysis by Wiseek.ai
Sentiment info
Positive
Importance info
8
Price
$6.38
Mkt Cap
$73.028M
52W Low
$3.2
52W High
$11.89
Market data snapshot near publication time

summarizeSummary

Falcon Creek Capital Advisor and its affiliated funds have finalized their $11 million investment in Cingulate Inc., acquiring a 28.5% beneficial ownership stake and securing board representation after receiving stockholder approval.


check_boxKey Events

  • Investment Finalized

    Falcon Creek Capital Advisor and affiliated funds completed an $11 million private placement, originally agreed upon January 27, 2026.

  • Stockholder Approval Received

    On March 24, 2026, stockholder approval was obtained, removing limitations on the conversion of preferred stock and the exercise of warrants. This event coincides with the company's recent launch of a $100 million ATM offering.

  • Significant Ownership Stake

    The investor group now beneficially owns 3,856,766 shares, representing approximately 28.50% of Cingulate's outstanding common stock.

  • Board Representation Secured

    The Falcon Creek group has the right to designate two directors to Cingulate's board, indicating significant influence.


auto_awesomeAnalysis

This amended Schedule 13D confirms the completion of a significant $11 million private placement by the Falcon Creek Capital Advisor group, which now beneficially owns 28.5% of Cingulate Inc. The key update is the receipt of stockholder approval on March 24, 2026, which removed prior limitations on the conversion of preferred stock and the exercise of warrants. This approval allows the investor group to fully realize their stake and influence, including the right to designate two directors. For a company that recently disclosed a going concern warning and launched a large ATM offering, this capital infusion and strategic investor backing are crucial for extending its operational runway and providing stability. The investment, priced at $5.14 per share (including warrant value), provides much-needed capital, although it is dilutive. The 180-day lock-up and 24-month standstill provisions offer a degree of protection against immediate share sales or hostile actions.

At the time of this filing, CING was trading at $6.38 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $73M. The 52-week trading range was $3.20 to $11.89. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.

descriptionView Main SEC Filing

show_chartPrice Chart

Share this article

Copied!

feed CING - Latest Insights

CING
Apr 28, 2026, 4:24 PM EDT
Filing Type: 424B3
Importance Score:
8
CING
Apr 14, 2026, 5:26 PM EDT
Filing Type: S-3
Importance Score:
8
CING
Mar 27, 2026, 4:01 PM EDT
Filing Type: 424B3
Importance Score:
8
CING
Mar 26, 2026, 4:24 PM EDT
Filing Type: SCHEDULE 13D/A
Importance Score:
8
CING
Mar 24, 2026, 5:14 PM EDT
Filing Type: 8-K
Importance Score:
9
CING
Mar 24, 2026, 5:13 PM EDT
Filing Type: 424B3
Importance Score:
9
CING
Mar 19, 2026, 6:00 PM EDT
Filing Type: S-3
Importance Score:
8
CING
Mar 18, 2026, 4:30 PM EDT
Filing Type: DEFA14A
Importance Score:
8
CING
Mar 18, 2026, 8:13 AM EDT
Filing Type: 10-K
Importance Score:
9
CING
Mar 18, 2026, 8:10 AM EDT
Filing Type: 8-K
Importance Score:
9